Edwards Lifesciences Corporation (NYSE:EW) has tumbled 2.94% during the past week and has dropped 0.58% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.77%. Edwards Lifesciences Corporation (NYSE:EW) has underperformed the index by 1.48% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $99.37 on Friday but the bulls could not build on the opening and the stock topped out at $99.65 for the day. The stock traded down to $97.76 during the day, due to lack of any buying support eventually closed down at $98.54 with a loss of -0.78% for the day. The stock had closed at $99.31 on the previous day. The total traded volume was 2,152,527 shares.
The company shares have dropped -31.72% from its 1 Year high price. On Apr 27, 2016, the shares registered one year high at $112.00 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $102.03 and the 200 Day Moving Average price is recorded at $93.53.
On the companys insider trading activities, Mussallem Michael A, director officer (Chairman & CEO) of Edwards Lifesciences Corp, unloaded 49,100 shares at an average price of $102.25 on June 8, 2016. The total amount of the transaction was worth $5,020,475, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Edwards Lifesciences Corporation (NYSE:EW).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on June 9, 2016. Currently the company Insiders own 2.37% of Edwards Lifesciences Corporation shares according to the proxy statements. Institutional Investors own 87.59% of Edwards Lifesciences Corporation shares.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.